Weekly Report on the Greater Health Industry: '2023 Internet Medical Services Insight Report' Released; Berry Genomics Plans Joint Venture and Asset Sale to Revitalize Assets

"2023 Internet Medical Service Insights Report" Released

Recently, VC Beat Eggshell Research Institute and JD Health jointly released the "2023 Internet Medical Services Insight Report——Exploring New Demands, Building a New Service System" to mine service data, analyze user needs, and construct a forward-looking framework for a new type of service system, aiming to provide inspiration for the industry. Sample data shows that users of internet medical services are mainly concentrated in first- and second-tier cities and sixth-tier cities, with a relatively smaller proportion of users from third-, fourth-, and fifth-tier cities, forming an overall "hourglass-shaped" distribution related to factors such as the layout of medical resources and user treatment needs. Currently, young people are the main users of online consultation and diagnosis, but elderly users already account for a certain proportion, and the percentage of middle-aged and elderly users is increasing year by year. (Source: VC Beat)

Berry Genomics Plans to Establish a Joint Venture and Sell Assets to Revitalize Company Assets

On February 4, 2024, Berry Genomics announced that its wholly-owned subsidiary, Fujian Berry Genomics Co., Ltd., holds a plot of land located in the Binhai New City, Changle District, Fuzhou City, with a land use area of 99,573 square meters. Fujian Berry has constructed the "Fujian Berry Genomics Digital Life Science Park" project on this plot, which includes Phase I South Area (completed and registered for property ownership), Phase I North Area (under construction), and Phase II Central Plot (not yet started). After the establishment of the joint venture, it will acquire all rights to the Fujian Industrial Park held by Fujian Berry (including but not limited to land use rights and above-ground structures) through an asset acquisition method, with an acquisition price of RMB 501.8 million. (Source: Zhitong Finance)

Novartis China and Fudan University Cancer Hospital Sign Strategic Cooperation Memorandum Again

On February 1, 2024, it was reported that according to the official WeChat account of Novartis Group, Novartis China and Fudan University Cancer Hospital recently renewed their Memorandum of Strategic Cooperation. The two parties will establish a comprehensive strategic partnership in areas such as research collaboration and platform development. (Source: Jiemian News)

Wondfo Biotech Obtains Patent for Building Medical Institution Database, Enhancing Accuracy of Medical Institution Information

On February 1, 2024, Wondfo Biotech obtained a patent named "Method for Constructing Medical Institution Database, Query Method, Device, Equipment, and Medium," with the publication number CN111899822B. The application date was June 2020. This application involves a method for constructing a medical institution database, a method for querying medical institution data, a device, computer equipment, and a storage medium. The method includes: obtaining medical institution data to be processed; extracting regional information and type information of each medical institution from the data; converting the regional and type information into descriptive information for each institution according to a preset standardized format, resulting in multiple first-level institutional descriptions; deduplicating and merging these descriptions to generate multiple second-level institutional descriptions; and based on the second-level descriptions, constructing a database for the medical institutions. This method avoids issues such as inconsistent naming, lack of standardization, duplicate names, aliases, typos, and missing information, eliminates the need for manual review, and improves the accuracy of medical institution information. (Source: Vbdata)

Rapid Medical Completes $10 Million A++ Round Financing

Recently, Rebecca Tech (hereinafter referred to as "Rebecca"), a leading domestic micro-electromechanical radio frequency technology manufacturer, announced the completion of a multi-million-dollar A++ round of financing. This round of financing was led by Mifang Health Fund, with Puhua Leading following the investment, and DSC Capital continuing to serve as the exclusive financial advisor. The funds raised from this round of financing will mainly be used for the promotion of the international exclusive micro-radio frequency general product line and the registration and certification of new products in the Middle East, America, and Europe. (Source: Arterial Network)

Pathology Medical Completes B-round Strategic Financing

Recently, Guangzhou Perceive Medical Technology Co., Ltd. ("Perceive Medical" for short) announced the successful completion of a 90 million RMB B-round strategic financing led by Zhuji Xieno Xingshi Venture Capital Partnership. Pedas Capital served as the exclusive financial advisor for this round. The funds from this round will mainly be used to further enhance and enrich the company’s product pipeline layout and innovation capabilities in the global intelligent tumor precision treatment market, which is worth hundreds of billions of dollars. Additionally, it will expand coverage in both domestic and international markets, accelerating the research, development, production, and registration of integrated software and hardware solutions for intelligent tumor precision treatment. Meanwhile, Perceive Medical will establish itself at Zhuji's Intelligent Vision "10,000 Mu, 100 Billion" New Industrial Platform (referred to as "Zhuji Intelligent Vision Industrial Platform"), fully advancing Perceive Medical’s strategic layout in East China and the R&D and production capacity construction of intelligent tumor precision surgical products. (Source: Arterial Network)

Zhongke Borui Completes Tens of Millions of Yuan in Series A Strategic Financing

Recently, Zhongke Borui (Beijing) Technology Co., Ltd. (hereinafter referred to as "Zhongke Borui") announced the completion of a multi-million yuan Series A strategic financing round. This round of financing was exclusively invested by Beijing Yi'an Medical Systems Co., Ltd. (hereinafter referred to as "Yi'an Medical"). The funds raised from this round of financing will be mainly used to accelerate the clinical trial process of multiple product lines, innovative product research and development, as well as marketing and sales efforts. (Source: Arterial Network)

Aoli Biotech Completes Tens of Millions in Pre-A Funding Round

Recently, Shenzhen Oralead Pharma Ltd. announced the completion of a multi-million yuan Pre-A round of financing, jointly invested by Hony Capital, Bori Biomedical (Suzhou) Co., Ltd. (a STAR Market listed company), and Bangqin Capital. The funds will mainly be used to advance the core pipeline of oral GLP-1 formulations and accelerate the construction of an oral delivery technology platform for biopharmaceuticals. (Source: Arterial Network)

Guangzheng Ophthalmology Releases 2023 Earnings Forecast

On January 29, 2024, Guangzheng Ophthalmology released its 2023 annual earnings forecast, predicting a net profit attributable to shareholders of the listed company between RMB 8 million and RMB 12 million, representing a turnaround from losses to profits year-on-year. The main reasons for the growth in performance and the turnaround during the reporting period are: 1. In 2023, China's economy improved overall, with annual GDP growth recovering to above 5%. After experiencing a complex environment in 2022, China’s consumer market gradually recovered. 2. In 2023, the company leased part of its energy and steel structure assets, improving asset utilization efficiency and enhancing profitability; although costs and expenses increased relatively for newly opened hospitals and clinics in the healthcare sector, the increase in ophthalmic revenue drove an overall improvement in profitability. (Source: Zhitong Finance)

Beijing to Prioritize Cell Gene Therapy and Synthetic Bio-Manufacturing as Key Tasks for 2024

Recently, the Beijing Municipal People's Government issued the "List of Key Tasks for the 2024 Government Work Report," clarifying the economic and social development goals and key tasks for 2024. Item 124 states: Leverage the advantages in quality and efficiency of clinical research, strengthen the development of original new drugs and high-end medical devices, utilize the role of the drug and medical device innovation service station, strive for pilot programs to accelerate the review of innovative drugs and medical devices, and improve the process for innovative drugs to enter hospitals. Strengthen the layout in cutting-edge emerging fields such as cell and gene therapy, synthetic biomanufacturing, and promote the formation of a clustered development trend. (Source: Arterial Network)